about
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part oneWidespread alternative exon usage in clinically distinct subtypes of Invasive Ductal CarcinomaThe Modular Adaptive Ribosome.Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinomaIdentifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid TumorsEndogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma.
P50
Q28553703-122E3D29-13E3-4453-92AA-4B8B146B4A69Q33911898-EBD81EB5-3E10-4D46-81DA-AEC51820F7C0Q36182339-A362C0F7-49A8-40C6-B51E-B286FDF04F6AQ36951751-E8E8802A-7618-4E51-97B8-CE3502CC6C5CQ47443241-8D8B982B-AD43-4712-B8CA-9B6751E99FF5Q56929146-343C3CBC-0748-4611-93A3-1E314676357FQ57216049-7F4C80B5-EA2A-4875-9720-FC41C28FC90CQ64894187-2ACD4CDF-1463-4A99-B409-63BA7A5FE0DC
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Anshuman Panda
@ast
Anshuman Panda
@en
Anshuman Panda
@es
Anshuman Panda
@nl
Anshuman Panda
@sl
অংশুমান পাণ্ডা
@bn
type
label
Anshuman Panda
@ast
Anshuman Panda
@en
Anshuman Panda
@es
Anshuman Panda
@nl
Anshuman Panda
@sl
অংশুমান পাণ্ডা
@bn
prefLabel
Anshuman Panda
@ast
Anshuman Panda
@en
Anshuman Panda
@es
Anshuman Panda
@nl
Anshuman Panda
@sl
অংশুমান পাণ্ডা
@bn
P106
P31
P496
0000-0001-7917-0317